NCT06457997View on ClinicalTrials.gov

A Study of PHN-010 in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

July 31, 2027

Conditions
Lung CancerColon CancerEndometrial CancerOvarian CancerCervical CancerAdvanced Solid TumorAdvanced Cancer
Interventions
DRUG

PHN-010

PHN-010 is an ADC

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

22031

NEXT - Virginia, Fairfax

32804

AdventHealth, Orlando

37203

Sarah Cannon Research Institute, Nashville

77030

MD Anderson Cancer Center, Houston

78229

NEXT - San Antonio, San Antonio

98109

University of Washington/Fred Hutchinson Cancer Center, Seattle

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Pheon Therapeutics
All Listed Sponsors
lead

Pheon Therapeutics

INDUSTRY

NCT06457997 - A Study of PHN-010 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter